The promise of mRNA vaccines: a biotech and industrial perspective

mRNA technologies have the potential to transform areas of medicine, including the prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration of immunogen discovery to rapid response and multiple disease target manufacturing. A greater understanding of quality attrib...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Nicholas A. C., Kester, Kent E., Casimiro, Danilo, Gurunathan, Sanjay, DeRosa, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000814/
https://www.ncbi.nlm.nih.gov/pubmed/32047656
http://dx.doi.org/10.1038/s41541-020-0159-8
_version_ 1783494115562881024
author Jackson, Nicholas A. C.
Kester, Kent E.
Casimiro, Danilo
Gurunathan, Sanjay
DeRosa, Frank
author_facet Jackson, Nicholas A. C.
Kester, Kent E.
Casimiro, Danilo
Gurunathan, Sanjay
DeRosa, Frank
author_sort Jackson, Nicholas A. C.
collection PubMed
description mRNA technologies have the potential to transform areas of medicine, including the prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration of immunogen discovery to rapid response and multiple disease target manufacturing. A greater understanding of quality attributes that dictate translation efficiency, as well as a comprehensive appreciation of the importance of mRNA delivery, are influencing a new era of investment in development activities. The application of translational sciences and growing early-phase clinical experience continue to inform candidate vaccine selection. Here we review the state of the art for the prevention of infectious diseases by using mRNA and pertinent topics to the biotechnology and pharmaceutical industries.
format Online
Article
Text
id pubmed-7000814
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70008142020-02-11 The promise of mRNA vaccines: a biotech and industrial perspective Jackson, Nicholas A. C. Kester, Kent E. Casimiro, Danilo Gurunathan, Sanjay DeRosa, Frank NPJ Vaccines Review Article mRNA technologies have the potential to transform areas of medicine, including the prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration of immunogen discovery to rapid response and multiple disease target manufacturing. A greater understanding of quality attributes that dictate translation efficiency, as well as a comprehensive appreciation of the importance of mRNA delivery, are influencing a new era of investment in development activities. The application of translational sciences and growing early-phase clinical experience continue to inform candidate vaccine selection. Here we review the state of the art for the prevention of infectious diseases by using mRNA and pertinent topics to the biotechnology and pharmaceutical industries. Nature Publishing Group UK 2020-02-04 /pmc/articles/PMC7000814/ /pubmed/32047656 http://dx.doi.org/10.1038/s41541-020-0159-8 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Jackson, Nicholas A. C.
Kester, Kent E.
Casimiro, Danilo
Gurunathan, Sanjay
DeRosa, Frank
The promise of mRNA vaccines: a biotech and industrial perspective
title The promise of mRNA vaccines: a biotech and industrial perspective
title_full The promise of mRNA vaccines: a biotech and industrial perspective
title_fullStr The promise of mRNA vaccines: a biotech and industrial perspective
title_full_unstemmed The promise of mRNA vaccines: a biotech and industrial perspective
title_short The promise of mRNA vaccines: a biotech and industrial perspective
title_sort promise of mrna vaccines: a biotech and industrial perspective
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000814/
https://www.ncbi.nlm.nih.gov/pubmed/32047656
http://dx.doi.org/10.1038/s41541-020-0159-8
work_keys_str_mv AT jacksonnicholasac thepromiseofmrnavaccinesabiotechandindustrialperspective
AT kesterkente thepromiseofmrnavaccinesabiotechandindustrialperspective
AT casimirodanilo thepromiseofmrnavaccinesabiotechandindustrialperspective
AT gurunathansanjay thepromiseofmrnavaccinesabiotechandindustrialperspective
AT derosafrank thepromiseofmrnavaccinesabiotechandindustrialperspective
AT jacksonnicholasac promiseofmrnavaccinesabiotechandindustrialperspective
AT kesterkente promiseofmrnavaccinesabiotechandindustrialperspective
AT casimirodanilo promiseofmrnavaccinesabiotechandindustrialperspective
AT gurunathansanjay promiseofmrnavaccinesabiotechandindustrialperspective
AT derosafrank promiseofmrnavaccinesabiotechandindustrialperspective

Ejemplares similares